Aethlon Medical
Market Cap
US$5.4m
Last Updated
2019/09/23 23:30 UTC
Data Sources
Company Financials +
Executive Summary
Aethlon Medical, Inc., a medical technology company, focuses on addressing unmet needs in health and biodefense worldwide.
Snowflake
Fundamentals
Mediocre balance sheet with limited growth.
Risks
- Aethlon Medical has significant price volatility in the past 3 months.
- Aethlon Medical is covered by less than 3 analysts.
Share Price & News
How has Aethlon Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
2.4%
AEMD
1.1%
US Medical Equipment
-0.5%
US Market
1 Year Return
-76.8%
AEMD
7.9%
US Medical Equipment
0.9%
US Market
AEMD underperformed the Medical Equipment industry which returned 9.7% over the past year.
AEMD underperformed the Market in United States of America which returned 0.7% over the past year.
Share holder returns
| AEMD | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.4% | 1.1% | -0.5% |
| 30 Day | -10.4% | 3.1% | 4.8% |
| 90 Day | -24.5% | 3.6% | 2.3% |
| 1 Year | -76.8%-76.8% | 8.8%7.9% | 3.1%0.9% |
| 3 Year | -94.5%-94.5% | 70.9%65.8% | 45.5%36.0% |
| 5 Year | -95.6%-95.6% | 139.2%112.0% | 62.5%44.7% |
Price Volatility Vs. Market
How volatile is Aethlon Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall St
Some Aethlon Medical (NASDAQ:AEMD) Shareholders Have Copped A 96% Share Price Wipe Out6 months ago | Simply Wall St
What Type Of Shareholder Owns Aethlon Medical, Inc.'s (NASDAQ:AEMD)?8 months ago | Simply Wall St
What Investors Should Know About Aethlon Medical, Inc.'s (NASDAQ:AEMD) Financial StrengthValuation
Is Aethlon Medical undervalued based on future cash flows and its price relative to the stock market?
4.56x
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for Aethlon Medical to establish if it is available at moderate discount.
Unable to calculate intrinsic value for Aethlon Medical to establish if it is available at substantial discount.
Price Based on Earnings
Aethlon Medical is loss making, we can't compare its value to the US Medical Equipment industry average.
Aethlon Medical is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Aethlon Medical, we can't assess if its growth is good value.
Price Based on Value of Assets
Aethlon Medical is overvalued based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Aethlon Medical expected to perform in the next 1 to 3 years based on estimates from 1 analyst?
14.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Aethlon Medical's revenue is expected to grow significantly at over 20% yearly.
Aethlon Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.
Aethlon Medical's revenue growth is expected to exceed the United States of America market average.
Unable to compare Aethlon Medical's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
Unable to compare Aethlon Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Aethlon Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Aethlon Medical performed over the past 5 years?
15.9%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Aethlon Medical does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
Unable to compare Aethlon Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Aethlon Medical's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Aethlon Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Aethlon Medical has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Aethlon Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Aethlon Medical's financial position?
Financial Position Analysis
Aethlon Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Aethlon Medical's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Aethlon Medical's level of debt (87.7%) compared to net worth is high (greater than 40%).
Aethlon Medical had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
Balance Sheet
Low level of unsold assets.
Debt is covered by short term assets, assets are 3x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Aethlon Medical has less than a year of cash runway based on current free cash flow.
Aethlon Medical has less than a year of cash runway if free cash flow continues to grow at historical rates of 2.9% each year.
Next Steps
Dividend
What is Aethlon Medical's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Aethlon Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Aethlon Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Aethlon Medical has not reported any payouts.
Unable to verify if Aethlon Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Aethlon Medical has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Aethlon Medical's salary, the management and board of directors tenure and is there insider trading?
4.9yrs
Average management tenure
CEO
Timothy Rodell (68yo)
0.8yrs
Tenure
US$1,000,132
Compensation
Dr. Timothy C. Rodell, Jr., M.D., FCCP has been Interim Chief Executive Officer and Director at Aethlon Medical, Inc. since December 10, 2018. Dr. Rodell is a Managing Partner of MTR, Inc. Dr. Rodell is th ...
CEO Compensation Analysis
Timothy's remuneration is higher than average for companies of similar size in United States of America.
Insufficient data for Timothy to compare compensation growth.
Management Age and Tenure
4.9yrs
Average Tenure
65yo
Average Age
The tenure for the Aethlon Medical management team is about average.
Board Age and Tenure
4.0yrs
Average Tenure
70yo
Average Age
The tenure for the Aethlon Medical board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Jim Joyce (57yo)
Consultant
- Tenure: 0.8yrs
- Compensation: US$272.71k
Timothy Rodell (68yo)
Interim CEO & Director
- Tenure: 0.8yrs
- Compensation: US$1.00m
Jim Frakes (62yo)
CFO, Senior VP of Finance & Secretary
- Tenure: 9yrs
- Compensation: US$285.83k
Richard Tullis (74yo)
Consultant
- Tenure: 0yrs
Sunil Sawhney
Head of Clinical Studies
- Tenure: 14.5yrs
Board Members
Timothy Rodell (68yo)
Interim CEO & Director
- Tenure: 0.8yrs
- Compensation: US$1.00m
Ed Broenniman (83yo)
Director
- Tenure: 20.5yrs
- Compensation: US$79.00k
Nathan Levin
Member of Extracorporeal Therapy Advisory Board
- Tenure: 0yrs
Greg Kovacs
Member of Extracorporeal Therapy Advisory Board
- Tenure: 0yrs
Claudio Ronco
Member of Extracorporeal Therapy Advisory Board
- Tenure: 0yrs
Larry Cowgill
Member of Sepsis & Inflammation Advisory Board
- Tenure: 0yrs
Chuck Fisher (72yo)
Chairman & Member of extracorporeal Therapy Advisory Board
- Tenure: 1.8yrs
- Compensation: US$159.00k
John Kellum
Member of Extracorporeal Therapy Advisory Board
- Tenure: 0yrs
Chetan Shah (50yo)
Director
- Tenure: 6.3yrs
- Compensation: US$78.00k
David Ward
Member of Extracorporeal Therapy Advisory Board
- Tenure: 0yrs
Company Information
Aethlon Medical, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Aethlon Medical, Inc.
- Ticker: AEMD
- Exchange: NasdaqCM
- Founded:
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$5.450m
- Shares outstanding: 19.94m
- Website: https://www.aethlonmedical.com
Number of Employees
Location
- Aethlon Medical, Inc.
- 9365 Granite Ridge Drive
- Suite 100
- San Diego
- California
- 92123
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AEMD | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Mar 1999 |
| EJUN | BST (Boerse-Stuttgart) | Yes | Common Stock | DE | EUR | Mar 1999 |
Biography
Aethlon Medical, Inc., a medical technology company, focuses on addressing unmet needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/23 23:30 |
| End of Day Share Price | 2019/09/23 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.